Synosia appoints new VP of neuropharmacology
This article was originally published in Scrip
Executive Summary
Synosia Therapeutics (Switzerland) has appointed Dr Hans-Rudolf Olpe vice-president of neuropharmacology. Dr Olpe has more than 35 years' experience working in neuropharmacology and neurobiology. At Ciba, he served as head of the nervous system pharmacology department and subsequently head of the stroke and epilepsy department at Novartis, where his team developed rufinamide, one of the compounds now in the Synosia portfolio, and the seizure medication Trileptal.